Literature DB >> 57118

Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity.

N T Bech-Hansen, J E Till, V Ling.   

Abstract

Colchicine resistant (CHR) mutants of CHO cells with reduced permeability to colchicine display extensive cross-resistance to a number of apparently unrelated compounds including puromycin, daunomycin, emetine, ethidium bromide and gramicidin D. A positive correlation was observed between the level of cross-resistance and the relative hydrophobicity of these compounds. The mutants also showed increased (collateral) sensitivity to local anaesthetics (procaine, tetracaine, xylocaine and propanolol), steroid hormones (1-dehydrotestosterone, corticosterone and 5beta-pregnan-3,20-dione) and some Triton X compounds. In general, the degree of the pleiotropic response (cross-resistance or collateral sensitivity) correlated with the degree of colchicine resistance in mutant lines. These results are consistent with the pleiotropic phenotype being the result of the same mutation(s) which confer colchicine resistance and support a model for resistance in which the reduced permeability is assumed to be the result of an alteration in the modulation of the fluidity of the surface membrane.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 57118     DOI: 10.1002/jcp.1040880104

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  59 in total

Review 1.  Drug resistance in oncology: from concepts to applications.

Authors:  J L Cazin; P Gosselin; P Cappelaere; J Robert; A Demaille
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 2.  Collateral sensitivity as a strategy against cancer multidrug resistance.

Authors:  Kristen M Pluchino; Matthew D Hall; Andrew S Goldsborough; Richard Callaghan; Michael M Gottesman
Journal:  Drug Resist Updat       Date:  2012-04-06       Impact factor: 18.500

3.  In situ biochemical demonstration that P-glycoprotein is a drug efflux pump with broad specificity.

Authors:  Y Chen; S M Simon
Journal:  J Cell Biol       Date:  2000-03-06       Impact factor: 10.539

4.  Isolation and characterization of an uncoupler-resistant mutant of Saccharomyces cerevisiae.

Authors:  C H Dupont; R Caubet; J P Mazat; B Guerin
Journal:  Curr Genet       Date:  1984-09       Impact factor: 3.886

5.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

Authors:  C Cordon-Cardo; J P O'Brien; D Casals; L Rittman-Grauer; J L Biedler; M R Melamed; J R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

6.  Intravesical chemotherapy: combination with Tween 80 increases cytotoxicity in vitro.

Authors:  C N Parris; J R Masters; M C Walker; B Newman; P Riddle; P English
Journal:  Urol Res       Date:  1987

Review 7.  Quantitative genetic analysis of tumor progression.

Authors:  V Ling; A F Chambers; J F Harris; R P Hill
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

8.  Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry.

Authors:  K Nooter; R Oostrum; R Jonker; H van Dekken; W Stokdijk; G van den Engh
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  DNA-mediated transfer of multiple drug resistance and plasma membrane glycoprotein expression.

Authors:  P G Debenham; N Kartner; L Siminovitch; J R Riordan; V Ling
Journal:  Mol Cell Biol       Date:  1982-08       Impact factor: 4.272

10.  Functional replacement of the hemolysin A transport signal by a different primary sequence.

Authors:  F Zhang; D I Greig; V Ling
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.